Compare DuPont de Nemours Inc (DD) vs Summit Therapeutics Inc (SMMT) Price & Performance

DuPont (DD) trades at $130.00, down 0.82% on the day, with a neutral technical signal and mixed financial trends. Recent earnings beats in Q4 2025, Q1 2026, and Q2 2026 contrast with a net loss of $779 million in 2025, though 2026 forecasts show a return to profitability. The company faces headwinds from PFAS litigation settlements and volatile cash flows, but innovation in areas like Tyvek and water technology supports long-term growth prospects.

The outlook for DD is cautiously optimistic, driven by secular growth in healthcare and water technologies, but weighed down by legal liabilities and margin pressures. Analyst consensus is bullish with a 58.54% buy rating, though the $95.00 price target suggests downside risk from current levels. Key risks include ongoing litigation costs and economic sensitivity in construction markets.

Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.

The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.